Genentech announced that BRIM3, a Phase 3 clinical study of RG7204, met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.
Merck KGaA highlighted a further analysis of the Phase 2 OPUSa study demonstrating an association between early tumor shrinkage and long-term median overall survival of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer.
Shares of Alexza Pharmaceuticals Inc. sank after the company said it will file a new application for its drug candidate Adusuve Staccato in July. Alexza expects the Food and Drug Administration to take six months to review its new submission.
When drugmaker Pfizer Inc. announced four years ago it would close its massive research and development center in Ann Arbor - the home of University of Michigan - academic and government leaders were stunned at the punch in the economic gut.
There's new hope for an overlooked epidemic: Two powerful drugs are nearing the market that promise to help cure many more people of liver-attacking hepatitis C - even though most who have the simmering infection don't know it yet.
Forest Laboratories Inc. said its profit jumped 53 percent in its fiscal third quarter on greater sales of its key drugs and lower expenses. Forest said its net income rose to $320.7 million, or $1.11 per share in the three months ended Dec. 31.
Mylan Inc., a generic drugmaker, said it received approval to make three doses of a generic version of Bayer's Precose tablets, which are used to treat diabetes.
Depomed Inc. said it will start mediation with Abbott Laboratories over a disagreement about the launch of a drug candidate for shingles-related pain.
More than 150 protein biopharmaceuticals have been approved for clinical use, but hundreds more have fallen by the wayside. In clinical trials, many therapeutic candidate proteins are frequently found to be immunotoxic and induce anti-drug antibody responses.
Shimadzu’s GC-2010 Plus and GC-2014, which feature high-precision analysis, excellent peak reproducibility, and high sensitivity levels, can now be controlled in an Empower environment.
Thermo Fisher Scientific Inc. launched new KingFisher nucleic acid purification kits that enable faster throughput and more rapid results. The kits contain all relevant buffers and reagents and are designed and optimized for use with KingFisher magnetic particle processors.
The Multiple Myeloma Research Foundation announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program.
Travel just one millimeter inside the brain and you'll be stepping into the dark. Standard light microscopes don't allow researchers to look into the interior of the living brain, where memories are formed and diseases such as dementia and cancer can take their toll.
In a technique that could eventually shed light on how gene expression influences human disease, scientists have for the first time ever successfully visualized single molecules of naturally-occurring messenger RNA transcribed in living mammalian cells.
Hudson Robotics announces an addition to its SOLO family of liquid handling workstations. The SOLO is an automated pipette workstation that is available with a single channel, 8- or 12-channel pipette option.